Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Joan Mannick on Rapamycin Longevity Series | Turning down mTOR to young levels may be good for aging
-
Narrated by:
-
By:
About this listen
Dr Joan Mannick is one of the world’s leading rapamycin and mTOR researchers in the longevity field. Joan has a background in academic medicine and is currently CEO at her own company Tornado Therapeutics where they focus on developing the next generation of mTOR inhibitors. One of the company goals is to create a mTOR inhibitor which is better than Rapamycin. Throughout the years Joan has made important discoveries in humans when it comes to finding a connection between mTOR inhibition and improvement of the aging immune system. In this podcast we are going to talk about her research, drug development, mTOR, rapamycin, rapalogs and other interesting longevity topics.
Links
https://www.tornado-tx.com
Joan's LinkedIn
Joan’s research publications
Big thanks to TimePie for the research help for this episode
Rapamycin resources
Rapamycin.news
Rapamycin Facebook group
Rapamycin Reddit group
Connect with Krister on:
Disclaimer: The podcast is for general information and educational purposes only and is not medical advice for you or others. The use of information and materials linked to the podcast is at the users own risk. Always consult your physician with anything you do regarding your health or medical condition.